Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flu H5 Egg Pandemic high dose vaccine, with adjuvant
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Flu H5 Egg Pandemic high dose vaccine, with adjuvant is an investigational monovalent influenza vaccine developed by Sanofi for pandemic preparedness. It utilizes an egg-based manufacturing process to produce antigens derived from the H5N8 strain of Influenza A. This specific formulation is a "high dose" version, containing a greater concentration of the hemagglutinin (HA) protein compared to standard doses, and is combined with Novavax's Matrix-M adjuvant. Matrix-M is a saponin-based adjuvant designed to enhance the magnitude and breadth of the immune response, potentially providing better protection against emerging pandemic strains. The vaccine is currently being evaluated in Phase 1/2 clinical trials for safety and immunogenicity in healthy adults.
- Other names
- Flu H5 Egg Pandemic high dose vaccine, with adjuvantH5N8 Matrix-M adjuvanted vaccineH-5N8 Matrix-M adjuvanted vaccineH 5N8 Matrix-M adjuvanted vaccineSanofi H5N8 vaccine
02
Targets
H5 HA (Influenza A hemagglutinin H5)Influenza A neuraminidase and conserved non-HA influenza antigens
Beyond the preview
Go deeper on Flu H5 Egg Pandemic high dose vaccine, with adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flu H5 Egg Pandemic high dose vaccine, with adjuvant.